Peptides / Recovery and repair

Synthetic analog · 39 amino acids · 4,103 Da

Vosoritide

ApprovedNot banned in sport

Vosoritide (Voxzogo) is a C-type natriuretic peptide analog approved in the US and EU for achondroplasia in children whose growth plates are still open. Studies in people tested it mostly on bone, growth and quality of life, and tracked side effects. PepBank shows 290 results on vosoritide from 45 studies in people, and 16 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Voxzogo

39 amino acids, from first to last0 changed amino acids

Evidence level: Large trials in people290 of 306 results come from studies in people, including randomized trials.

Results in people

290

95% of 306 results

Results in animals

5% of 306 results

Results in lab cells

under 1% of 306 results

From computer models

0% of 306 results

Overview

Vosoritide at a glance

What it is	Synthetic analog, 39 amino acids
Approval	Approved in the US and EU (Voxzogo)
In sport	Not listed as banned by WADA
Studies	50 studies with results. All of them gave vosoritide, with 306 results. 290 in people14 in animals2 in lab cells
Best study in people	Randomized controlled trial with 121 people (2020)
Clinical trials	16 registered: 12 active or planned, 3 with posted results
Community use	Pediatric achondroplasia with open epiphyses

The science

What is vosoritide?

Vosoritide is a 39-residue C-type natriuretic peptide analog.

Amino acids in one chain

The history of vosoritide

2014January
A registered trial of vosoritide started (NCT02055157).
2019
The oldest paper on vosoritide in PepBank is from 2019.

Vosoritide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 39 amino acidsFrom the first amino acid to the last

P1GQ−EH5PNA+R+K10Y+KGAN15+K+KGLS20+KGCFG25L+KL−D+R30IGSMS35GLGC

Darker means more water-repelling+ and − show charge in the body

Structure

Vosoritide is a synthetic analog of 39 amino acids, with a ring, 1 disulfide bond, no changed amino acids.

Formula

C₁₇₆H₂₉₀N₅₆O₅₁S₃

Molecular weight

4,103 g/mol

CAS number

1480724-61-5

Target

Natriuretic peptide receptor B (gene NPR2): agonistEvidence: Official prescribing information, mechanism of action

Development

BioMarin Pharmaceutical Inc. Highest phase: past the trial stage (see status).

Identifiers

PubChem 119058036, ChEMBL CHEMBL3707276, UNII 7SE5582Q2P, DrugBank DB11928

Full sequence, SMILES and InChIKey

InChIKey
IGYWDDBBJPSOTG-WBAGYEQSSA-N

SMILES
CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO

See charge, composition and 3D structure on the Scientific page

The evidence

What vosoritide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people290 of 306 results come from studies in people, including randomized trials.

Bones and joints

141 results · 130 in people · 11 animal

In children with achondroplasia, vosoritide increased annualized growth velocity by 1.57 cm/year compared with placebo. Journal of the Endocrine Society, 2020

Top results

In children with achondroplasia, vosoritide increased annualized growth velocity by 1.57 cm/year compared with placebo. (Journal of the Endocrine Society, 2020)
In young children with achondroplasia, height score change favored vosoritide over placebo, but the confidence interval included zero. (The Lancet. Child & adolescent health, 2024)
In older children with achondroplasia, tibial bowing remained stable with vosoritide compared with placebo. (Journal of the Endocrine Society, 2026)

Daily life and fitness

25 results · 25 in people

In children receiving vosoritide, caregiver-reported physical scores increased from baseline at year 3. Genetics in medicine, 2024

Top results

In children receiving vosoritide, caregiver-reported physical scores increased from baseline at year 3. (Genetics in medicine, 2024)
In children with achondroplasia, raw jumping measures increased numerically during vosoritide treatment, except relative force. (Journal of musculoskeletal & neuronal interactions, 2026)
All caregivers of children receiving vosoritide expressed willingness to recommend treatment. (American journal of medical genetics. Part A, 2026)

Growth hormone and growth

17 results · 17 in people

In children with hypochondroplasia, vosoritide increased growth velocity more than placebo at week 52. NEJM evidence, 2026

Top results

In children with hypochondroplasia, vosoritide increased growth velocity more than placebo at week 52. (NEJM evidence, 2026)
In children with hypochondroplasia, IGF-1 increased across a study that included observation before vosoritide treatment. (The Journal of clinical endocrinology and metabolism, 2026)
In children with achondroplasia, growth velocity increased with vosoritide dose up to 15.0 μg per kilogram during the first 6 months. (The New England journal of medicine, 2019)

Survival and serious illness

6 results · 6 in people

One young child receiving vosoritide died and discontinued the study. The Lancet. Child & adolescent health, 2024

Top results

One young child receiving vosoritide died and discontinued the study. (The Lancet. Child & adolescent health, 2024)
One child receiving vosoritide with pre-existing respiratory morbidity had a fatal respiratory arrest. (Journal of the Endocrine Society, 2022)
No deaths were observed in children receiving vosoritide. (Med, 2025)

Eyes

5 results · 5 in people

In children receiving vosoritide, nasal retinal thickness increased nominally, but the change was not significant after correction. Journal of clinical medicine, 2026

Top results

In children receiving vosoritide, nasal retinal thickness increased nominally, but the change was not significant after correction. (Journal of clinical medicine, 2026)
In children receiving vosoritide, retinal vascular densities showed no significant changes over time. (Journal of clinical medicine, 2026)
In children receiving vosoritide, average retinal nerve fiber thickness increased nominally, but the change was not significant after correction. (Journal of clinical medicine, 2026)

Heart and blood vessels

3 results · 3 in people

In children with achondroplasia, vosoritide exposure showed no meaningful link to systolic blood pressure changes. Clinical pharmacokinetics, 2022

Top results

In children with achondroplasia, vosoritide exposure showed no meaningful link to systolic blood pressure changes. (Clinical pharmacokinetics, 2022)
In children with achondroplasia, vosoritide exposure showed no meaningful link to heart rate changes from predose values. (Clinical pharmacokinetics, 2022)
In children with achondroplasia, vosoritide exposure showed no meaningful link to diastolic blood pressure changes. (Clinical pharmacokinetics, 2022)

All 50 vosoritide studies by area Open the Scientific page

Key vosoritide studies

Studies in people come first, then studies in animals and in the lab.

People
SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
Savarirayan et al. 2020 · Journal of the Endocrine Society · 121 people · cited by 0
2 results
People
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia
Dauber et al. 2026 · NEJM evidence · 81 people · cited by 0
5 results
People
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
Savarirayan et al. 2024 · The Lancet. Child & adolescent health · 75 people · cited by 59
9 results
People
Effect of vosoritide on genu varum in children with achondroplasia after 1 year in randomized placebo-controlled trials
White et al. 2026 · Journal of the Endocrine Society · 57 people · cited by 1
7 results
People
Effect of vosoritide on spine morphology in children with achondroplasia: 1-year results from a randomized phase 2 study
Irving et al. 2026 · Journal of the Endocrine Society · cited by 1
7 results

All 50 Vosoritide studies

Vosoritide clinical trials

ClinicalTrials.gov lists 16 trials of vosoritide. 12 are active or planned, and 3 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Phase 3completed121 people

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Phase 2/3recruiting160 planned

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

Phase 3enrolling by invitation140 planned

All 7 Vosoritide trials

Status and safety

Is vosoritide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Voxzogo). The FDA label for Voxzogo says: “Pediatric achondroplasia with open epiphyses” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Vosoritide side effects and safety

PepBank has 90 safety results from studies of vosoritide. 90 of them come from studies in people.

Safety results from studies (90)

In children with achondroplasia, adverse events were similar with vosoritide (98.3%) and with placebo (98.4%). (Journal of the Endocrine Society, 2020)
In children with hypochondroplasia, adverse events occurred in 87.8% with vosoritide versus 72.5% with placebo. (NEJM evidence, 2026)
All young children receiving vosoritide experienced adverse events, as did all study participants. (The Lancet. Child & adolescent health, 2024)
In young children with achondroplasia, every patient reported at least one adverse event, including patients given placebo. (Journal of the Endocrine Society, 2022)
In children with these growth disorders, mild injection site reactions were the most common adverse events in the short term with vosoritide. (The Journal of clinical endocrinology and metabolism, 2026)
No treatment-related serious adverse events occurred in children with hypochondroplasia receiving vosoritide. (EClinicalMedicine, 2024)
Vosoritide had a favorable safety profile in children with achondroplasia during continuous treatment for up to 6 years. (Med, 2025)
In children with achondroplasia, 25 of 60 vosoritide-treated patients developed antibody responses (42%). (Clinical pharmacokinetics, 2022)
In children with achondroplasia, all vosoritide recipients had adverse events during treatment. (The New England journal of medicine, 2019)
No SCFE occurred in the 24 participants with hypochondroplasia during vosoritide therapy. (Hormone research in paediatrics, 2026)
In children with achondroplasia receiving vosoritide, no new adverse effects were detected. (Genetics in medicine, 2021)
In children with genetic short stature receiving vosoritide, no treatment-related serious adverse events occurred. (Journal of the Endocrine Society, 2022)
In children with achondroplasia receiving vosoritide, all reported adverse events were mild. (Hormone research in paediatrics, 2026)
Children with achondroplasia receiving vosoritide had frequent but mild adverse events, mainly injection-site reactions. (American journal of medical genetics. Part A, 2026)
In children with achondroplasia receiving vosoritide, excess hair growth occurred in 66% of patients. (Hormone research in paediatrics, 2026)
In children receiving vosoritide, injection site reactions were the most common adverse drug reaction. (Advances in therapy, 2025)
In children with achondroplasia receiving vosoritide, no serious treatment-related adverse events occurred. (Journal of the Endocrine Society, 2026)
In children with achondroplasia receiving vosoritide, three patients reported injection site pain. (Bone, 2026)
No clinically relevant eye disease was identified in children with achondroplasia during vosoritide treatment. (Journal of clinical medicine, 2026)
In adverse event reports, vosoritide was linked to a joint deformity reporting signal. (Clinical and experimental rheumatology, 2026)
In vosoritide trial participants, complication prevalence included past medical history and new events, and was generally similar to or below natural history rates. (Genetics in medicine, 2026)
Vosoritide monotherapy reports included notable adverse event reporting in children. (PloS one, 2026)
In children with achondroplasia receiving vosoritide, 11 of 18 developed excess hair growth. (Journal of medical case reports, 2025)
Two infants with achondroplasia had no serious adverse events during short-term vosoritide monitoring. (American journal of medical genetics. Part A, 2026)

See every safety result on the Scientific page

Doses studied (25 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
15 μg/kg once daily	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 121	Savarirayan 2020
30.0 μg/kg for ages 0-23 months; 15.0 μg/kg for ages 24-59 months	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 64	Savarirayan 2024
15 or 30 µg/kg/day	Human	human	Not reported	1 year	Randomized trial in people · n = 57	White 2026
15 or 30 μg/kg once daily	Human	human	subcutaneous	52 weeks	Trial in people without random groups · n = 75	2022
15 µg/kg/day	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 30	Dauber 2026
15 μg/kg/day	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 24	Dauber 2024
15 mcg/kg/day	Human	human	subcutaneous	Not reported	Trial in people without random groups	2022
15 μg/kg daily	Human	human	Not reported	up to 6 years	Trial in people without random groups · n = 119	Savarirayan 2025
15 μg/kg	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 60	Chan 2022
15 μg/kg/day	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 24	Galetaki 2026
2.5 to 15.0 μg per kilogram once daily	Human	human	subcutaneous	6 months	Trial in people without random groups	Savarirayan 2019
15.0 μg per kilogram once daily	Human	human	subcutaneous	Not reported	Trial in people without random groups	Savarirayan 2019
30.0 μg per kilogram once daily	Human	human	subcutaneous	Not reported	Trial in people without random groups	Savarirayan 2019
15.0 μg/kg/day	Human	human	Not reported	two years	Trial in people without random groups	Savarirayan 2021
15 μg/kg/day	Human	human	Not reported	Not reported	Trial in people without random groups	Savarirayan 2024
15 μg/kg/day	Human	human	subcutaneous	Not reported	Trial in people without random groups	Kanakatti 2026
15 μg/kg once daily	Human	human	subcutaneous	Not reported	Observational study · n = 57	Cormier-Daire 2026
30 μg/kg	Human	human	subcutaneous	Not reported	Observational study	Chan 2022
15 µg/kg	Human	human	subcutaneous	Not reported	Observational study	Chan 2022
2.5-30 μg/kg/day	Human	human	Not reported	Not reported	Observational study	Savarirayan 2026
0.24 mg; 53 μg/kg	Human	human	injection	Not reported	Reports of single patients · n = 1	Satake 2026
15 µg/kg/day, increased to 30 µg/kg/day after 16 months	Human	human	subcutaneous	28 months	Reports of single patients · n = 1	Montero-Lopez 2025
20 µg/kg	Animal	Not reported	subcutaneous	Not reported	Study in live animals	Breinholt 2019
10-4M	Lab	human	Not reported	Not reported	Study on cells in a dish	Demuynck 2020
10-5M	Lab	human	Not reported	Not reported	Study on cells in a dish	Demuynck 2020

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes Voxzogo for pediatric achondroplasia with open epiphyses. This record selects one label regimen.

Reported routines and cautions

What people use it for

Pediatric achondroplasia with open epiphysesS1

Reported regimens

Regimens that community sources report for Vosoritide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
US-label Voxzogo lyophilized powder for reconstitution, for pediatric achondroplasia with open epiphyses.Official label dosing of an approved product	subcutaneous injection	Not stated	once daily	Until epiphyseal closure	Single official US label source.	S1

Cautions

The label warns about transient low blood pressure.S1
The US label does not recommend Voxzogo for patients with eGFR below 60 mL/min/1.73 m².S1

Status notes

Voxzogo has EU marketing authorisation. The selected regimen uses the US label.S2

Community sources

S1Voxzogo US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This review does not establish a separate non-vendor community regimen. This record selects one US label regimen without a fixed dose amount. Table 1 and actual body weight determine dose selection. The full label contains the complete preparation, storage and administration instructions.

Questions and more

Ask a question about vosoritide

The answer links to every study it uses.

What does the evidence say about vosoritide?Is vosoritide tested in people?Compare with Teriparatide (PTH 1-34)Compare with BPC-157

Sources

Database: PepBank data for vosoritide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about vosoritide

Vosoritide

ApprovedNot banned in sport

Also known as Voxzogo

What it is

Synthetic analog, 39 amino acids

Approval

Approved in the US and EU (Voxzogo)

In sport

Not listed as banned by WADA

Studies

50 studies with results. All of them gave vosoritide, with 306 results.
290 in people14 in animals2 in lab cells

Best study in people

Randomized controlled trial with 121 people (2020)

Clinical trials

16 registered: 12 active or planned, 3 with posted results

Community use

Pediatric achondroplasia with open epiphyses

Dose as reported

Class

Species

Route

Duration

Design

Source

15 μg/kg once daily

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 121

Savarirayan 2020

30.0 μg/kg for ages 0-23 months; 15.0 μg/kg for ages 24-59 months

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 64

Savarirayan 2024

15 or 30 µg/kg/day

Human

human

Not reported

1 year

Randomized trial in people · n = 57

White 2026

15 or 30 μg/kg once daily

Human

human

subcutaneous

52 weeks

Trial in people without random groups · n = 75

2022

15 µg/kg/day

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 30

Dauber 2026

15 μg/kg/day

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 24

Dauber 2024

15 mcg/kg/day

Human

human

subcutaneous

Not reported

Trial in people without random groups

2022

15 μg/kg daily

Human

human

Not reported

up to 6 years

Trial in people without random groups · n = 119

Savarirayan 2025

15 μg/kg

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 60

Chan 2022

15 μg/kg/day

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 24

Galetaki 2026

2.5 to 15.0 μg per kilogram once daily

Human

human

subcutaneous

6 months

Trial in people without random groups

Savarirayan 2019

15.0 μg per kilogram once daily

Human

human

subcutaneous

Not reported

Trial in people without random groups

Savarirayan 2019

30.0 μg per kilogram once daily

Human

human

subcutaneous

Not reported

Trial in people without random groups

Savarirayan 2019

15.0 μg/kg/day

Human

human

Not reported

two years

Trial in people without random groups

Savarirayan 2021

15 μg/kg/day

Human

human

Not reported

Trial in people without random groups

Savarirayan 2024

15 μg/kg/day

Human

human

subcutaneous

Not reported

Trial in people without random groups

Kanakatti 2026

15 μg/kg once daily

Human

human

subcutaneous

Not reported

Observational study · n = 57

Cormier-Daire 2026

30 μg/kg

Human

human

subcutaneous

Not reported

Observational study

Chan 2022

15 µg/kg

Human

human

subcutaneous

Not reported

Observational study

Chan 2022

2.5-30 μg/kg/day

Human

human

Not reported

Observational study

Savarirayan 2026

0.24 mg; 53 μg/kg

Human

human

injection

Not reported

Reports of single patients · n = 1

Satake 2026

15 µg/kg/day, increased to 30 µg/kg/day after 16 months

Human

human

subcutaneous

28 months

Reports of single patients · n = 1

Montero-Lopez 2025

20 µg/kg

Animal

Not reported

subcutaneous

Not reported

Study in live animals

Breinholt 2019

10-4M

Lab

human

Not reported

Study on cells in a dish

Demuynck 2020

10-5M

Lab

human

Not reported

Study on cells in a dish

Demuynck 2020

Context

Route

Amount

How often

How long

Agreement

Sources

US-label Voxzogo lyophilized powder for reconstitution, for pediatric achondroplasia with open epiphyses.Official label dosing of an approved product

subcutaneous injection

Not stated

once daily

Until epiphyseal closure

Single official US label source.

Vosoritide

Vosoritide at a glance

What is vosoritide?

The history of vosoritide

Vosoritide structure and chemistry

What vosoritide studies show

Bones and joints

Daily life and fitness

Growth hormone and growth

Survival and serious illness

Eyes

Heart and blood vessels

Key vosoritide studies

Vosoritide clinical trials

Is vosoritide approved?

Vosoritide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about vosoritide

Related peptides

Sources

Vosoritide

Vosoritide at a glance

What is vosoritide?

The history of vosoritide

Vosoritide structure and chemistry

What vosoritide studies show

Bones and joints

Daily life and fitness

Growth hormone and growth

Survival and serious illness

Eyes

Heart and blood vessels

Key vosoritide studies

Vosoritide clinical trials

Is vosoritide approved?

Vosoritide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about vosoritide

Related peptides

Sources